As part of broad­er gene ther­a­py am­bi­tions, Take­da links up again with a small Chica­go biotech

Take­da is ink­ing gene ther­a­py deals left and right. This time, it’s part­ner­ing for a sec­ond time with Chica­go-based pro­tein mak­er Evozyne.

Af­ter lin­ing up col­lab­o­ra­tions with Code Bio­ther­a­peu­tics, Po­sei­da Ther­a­peu­tics, Se­lec­ta Bio­sciences and Genevant in re­cent months, the Japan­ese phar­ma wants to go fur­ther in­to next-gen gene ther­a­pies. This time, Take­da and Evozyne will work on four rare dis­ease tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER